SgRNA Design and Confirmation    

CRISPR/Cas9 Platform^CB provides a series of sgRNA service, including sequence design, synthesis, validation of efficiency and off-target analysis. In the past decade, our talented scientists are focusing on the development of gene-editing technology and are following the latest technique in this field. Our staff is experienced in sgRNA design and efficiency analysis. We will work closely with you to bring you satisfied services and products.

Since the first description of CRISPR system, it becomes the most acceptable gene-editing tool in the world. The key components of CRISPR system are Cas9 nucleases and guide RNA. In term of targeting different sites genome, sgRNA varies the sequence to each target. A high-quality sgRNA is the foundation of successful gene-editing process. When to select the target sites of Cas9, the only requirement is the presence of PAM. There are multiple type Cas9 nucleases which require different PAMs. The most common used Cas9 nucleases are spCas9 and saCas9 and the PAM are ‘NGG’ and ‘NNGRRT’ respectively. By introducing the target sequence into sgRNA, the Cas9/sgRNA complex can specifically recognize the target sites. Cas9 introduces DNA double strand break after recruited to the specific site. Subsequently, DNA repair may induce random mutant resulting in gene inactivation.

Fig 1. Design sgRNA for spCas9 and saCas9 nucleases1

CRISPR/Cas9 Platform^CB brings customers a set of sgRNA service with high quality, including sgRNA design, construction and validation. Additionally, off-target analysis is available. We provide one of these services separately or a combined service depending on your needs. Before ordering, customers could contact us with your project for free consultation. We will offer feasible analysis for you on a ‘case by case’ basis. Once a project begins, our staff will work closely with you at all the time and keep in touch for each step. We are working to assist you for your goals.

For more information, please feel free to contact us.